Skip to main content

Development of cdna-arrays for quantifying expression levels of mrna and oligo-arrays for detecting genetic variants of drug metabolism genes: pharmagenarrays

Objective

The scientific goals of the proposed prom act are:
1) To develop a array-array system to profile expression levels of drug metabolising enzymes after exposure of cell cultures or whole animals to xenobiotics (drugs or environmental compounds) and
2) to develop an oligonucleotide-array system to detect variant alleles of genes that determine an individuals response to medicinal compounds (drugs) or determine an individuals risk on exposure to environmental toxins. Expression profiling of drug metabolising enzymes in animals and later in humans is a key component in the pre-clinical stages of new drug development in the pharmaceutical industry. Detection of variant alleles (genotyping), the second objective of the proposed collaboration, will address an emerging and far-reaching need in the pharmaceutical industry and in healthcare in general. The ultimate goal of this second objective is to develop a cost-effective method of pharmacogenetic profiling for use as a tool in clinical trial studies and in the longer term as a means of selecting the lost aoorioriate drug therapy for individual patients.

Funding Scheme

EAW - Exploratory awards

Coordinator

METABOLIC SYSTEMS CO
Address
C/o Biochemistry Dept., Trinity College
Dublin
Ireland

Participants (1)

AZIGN BIOSCIENCE A/S
Denmark
Address
Vestre Teglgade 10
2450 Koepenhagen